Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer

Revisiting autoimmune lymphoproliferative syndrome caused by Fas ligand mutations

(2023) Maria Elena Maccari et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies

(2022) Filippo Consonni et al.   ANNALS OF HEMATOLOGY

Differential Expression of Proteins in an Atypical Presentation of Autoimmune Lymphoproliferative Syndrome

(2022) Dulce María Delgadillo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy

(2022) Kristin G Anderson et al.   Journal for ImmunoTherapy of Cancer

Upgrade: Phase 1 combination trial of the NaPi2b-directed dolaflexin antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer (588)

(2022) Nehal Lakhani et al.   GYNECOLOGIC ONCOLOGY

Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand–Expressing Solid Tumors

(2022) Pradip Bajgain et al.   Cancer Immunology Research

Targeting NaPi2b in ovarian cancer

(2022) Susana Banerjee et al.   CANCER TREATMENT REVIEWS

cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis

(2022) Liqin Wang et al.   Nature Cancer

A critical role for fas-mediated off-target tumor killing in T cell immunotherapy

(2021) Ranjan Upadhyay et al.   Cancer Discovery

Unexpected PD‐L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies

(2021) Tanmoy Mondal et al.   EMBO Molecular Medicine

Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity

(2021) Stefan Kiesgen et al.   Nature Protocols

TCR β chain–directed bispecific antibodies for the treatment of T cell cancers

(2021) Suman Paul et al.   Science Translational Medicine

A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors

(2021) Gururaj Shivange et al.   Cell Reports

Author Correction: The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity

(2020) Alexandra Schnell et al.   CELL RESEARCH

Top 10 Challenges in Cancer Immunotherapy

(2020) Priti S. Hegde et al.   IMMUNITY

Death Receptors and Their Ligands in Inflammatory Disease and Cancer

(2020) Alessandro Annibaldi et al.   Cold Spring Harbor Perspectives in Biology

Higher-Order Clustering of the Transmembrane Anchor of DR5 Drives Signaling

(2019) Liqiang Pan et al.   CELL

Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

(2018) S Banerjee et al.   ANNALS OF ONCOLOGY

A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer

(2018) Gururaj Shivange et al.   CANCER CELL

Perturbing the Dynamics and Organization of Cell Membrane Components: A New Paradigm for Cancer-Targeted Therapies

(2018) Nuno Bernardes et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment

(2017) Oladapo O. Yeku et al.   Scientific Reports

Dual Role of Fas/FasL-Mediated Signal in Peripheral Immune Tolerance

(2017) Akiko Yamada et al.   Frontiers in Immunology

Crystal Structure of the Complex of Human FasL and Its Decoy Receptor DcR3

(2016) Weifeng Liu et al.   STRUCTURE

Targeting Negative Surface Charges of Cancer Cells by Multifunctional Nanoprobes

(2016) Bingdi Chen et al.   Theranostics

Abstract A115: The CD95 ligand inhibitor APG 101 reduces tumor recurrence and metastasis in an adjuvant orthotopic mouse model of pancreatic cancer as well as primary tumor load in a palliative setting

(2015) Freya Goumas et al.   CANCER RESEARCH

The role of CD95 and CD95 ligand in cancer

(2015) M E Peter et al.   CELL DEATH AND DIFFERENTIATION

TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2

(2015) Taro Tamada et al.   Scientific Reports

Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity

(2014) Jonathan D. Graves et al.   CANCER CELL

CD95 and CD95L promote and protect cancer stem cells

(2014) Paolo Ceppi et al.   Nature Communications

T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy

(2014) I. Melero et al.   Cancer Discovery

Conformational Coupling across the Plasma Membrane in Activation of the EGF Receptor

(2013) Nicholas F. Endres et al.   CELL

A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency

(2012) M Chodorge et al.   CELL DEATH AND DIFFERENTIATION

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer

(2012) Lana E Kandalaft et al.   Journal of Translational Medicine

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

(2011) Nicholas S. Wilson et al.   CANCER CELL

CD95 promotes tumour growth

(2010) Lina Chen et al.   NATURE

T-cell receptor complex is essential for Fas signal transduction

(2010) A. M. Akimzhanov et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Expression systems for therapeutic glycoprotein production

(2009) Yves Durocher et al.   CURRENT OPINION IN BIOTECHNOLOGY

CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling

(2009) Gudrun Strauss et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

(2008) C Adams et al.   CELL DEATH AND DIFFERENTIATION

Directing cancer cells to self-destruct with pro-apoptotic receptor agonists

(2008) Avi Ashkenazi   NATURE REVIEWS DRUG DISCOVERY

Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease

(2008) K. Takeda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA